CL2022002786A1 - Formas cristalinas de compuestos orgánicos - Google Patents
Formas cristalinas de compuestos orgánicosInfo
- Publication number
- CL2022002786A1 CL2022002786A1 CL2022002786A CL2022002786A CL2022002786A1 CL 2022002786 A1 CL2022002786 A1 CL 2022002786A1 CL 2022002786 A CL2022002786 A CL 2022002786A CL 2022002786 A CL2022002786 A CL 2022002786A CL 2022002786 A1 CL2022002786 A1 CL 2022002786A1
- Authority
- CL
- Chile
- Prior art keywords
- crystalline forms
- organic compounds
- compound
- useful
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063008161P | 2020-04-10 | 2020-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022002786A1 true CL2022002786A1 (es) | 2023-04-14 |
Family
ID=75690727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022002786A CL2022002786A1 (es) | 2020-04-10 | 2022-10-07 | Formas cristalinas de compuestos orgánicos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230151010A1 (https=) |
| EP (1) | EP4132930A1 (https=) |
| JP (2) | JP2023521411A (https=) |
| KR (1) | KR20230008742A (https=) |
| CN (1) | CN115916780A (https=) |
| AU (1) | AU2021253946A1 (https=) |
| BR (1) | BR112022020243A2 (https=) |
| CA (1) | CA3179957A1 (https=) |
| CL (1) | CL2022002786A1 (https=) |
| CO (1) | CO2022016067A2 (https=) |
| IL (1) | IL297206A (https=) |
| MX (1) | MX2022012523A (https=) |
| PE (1) | PE20231071A1 (https=) |
| WO (1) | WO2021207659A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA71692A (fr) | 2022-08-01 | 2025-05-30 | Bristol-Myers Squibb Company | Utilisation de milvexian pour le traitement ou la prévention d'un accident vasculaire cérébral ischémique |
| KR20250136432A (ko) | 2023-02-06 | 2025-09-16 | 브리스톨-마이어스 스큅 컴퍼니 | 밀벡시안 제약 조성물 |
| WO2025224678A1 (en) | 2024-04-25 | 2025-10-30 | Assia Chemical Industries Ltd. | Solid state forms of milvexian and process for preparation thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201908467RA (en) * | 2014-01-31 | 2019-10-30 | Bristol Myers Squibb Co | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors |
| NO2721243T3 (https=) * | 2014-10-01 | 2018-10-20 | ||
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
-
2021
- 2021-04-09 IL IL297206A patent/IL297206A/en unknown
- 2021-04-09 EP EP21722085.4A patent/EP4132930A1/en active Pending
- 2021-04-09 PE PE2022002222A patent/PE20231071A1/es unknown
- 2021-04-09 BR BR112022020243A patent/BR112022020243A2/pt unknown
- 2021-04-09 MX MX2022012523A patent/MX2022012523A/es unknown
- 2021-04-09 KR KR1020227039277A patent/KR20230008742A/ko active Pending
- 2021-04-09 CN CN202180039763.5A patent/CN115916780A/zh active Pending
- 2021-04-09 JP JP2022562082A patent/JP2023521411A/ja active Pending
- 2021-04-09 WO PCT/US2021/026663 patent/WO2021207659A1/en not_active Ceased
- 2021-04-09 AU AU2021253946A patent/AU2021253946A1/en active Pending
- 2021-04-09 CA CA3179957A patent/CA3179957A1/en active Pending
- 2021-04-09 US US17/995,848 patent/US20230151010A1/en active Pending
-
2022
- 2022-10-07 CL CL2022002786A patent/CL2022002786A1/es unknown
- 2022-11-09 CO CONC2022/0016067A patent/CO2022016067A2/es unknown
-
2025
- 2025-12-17 JP JP2025260150A patent/JP2026048873A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4132930A1 (en) | 2023-02-15 |
| BR112022020243A2 (pt) | 2022-11-22 |
| JP2026048873A (ja) | 2026-03-17 |
| PE20231071A1 (es) | 2023-07-17 |
| IL297206A (en) | 2022-12-01 |
| AU2021253946A1 (en) | 2022-12-15 |
| WO2021207659A1 (en) | 2021-10-14 |
| CO2022016067A2 (es) | 2023-01-26 |
| CN115916780A (zh) | 2023-04-04 |
| MX2022012523A (es) | 2022-11-07 |
| JP2023521411A (ja) | 2023-05-24 |
| US20230151010A1 (en) | 2023-05-18 |
| CA3179957A1 (en) | 2021-10-14 |
| KR20230008742A (ko) | 2023-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022002786A1 (es) | Formas cristalinas de compuestos orgánicos | |
| CO2021005226A2 (es) | Nuevos compuestos antihelmínticos | |
| CO2022002413A2 (es) | Composiciones y métodos para tratar la psoriasis y la dermatitis atópica usando prevotella histicola | |
| PE20220134A1 (es) | Compuestos de pirrolidina | |
| UY38160A (es) | Partículas implantables y métodos relacionados | |
| CO2020001244A2 (es) | Derivados de quinolina para tratar infecciones con helmintos | |
| DOP2018000226A (es) | Nuevos derivados de pirazolopirimidina | |
| CO2025000537A2 (es) | Compuestos heteroarílicos como degradadores de irak4 dirigidos por el ligando | |
| CR20140113A (es) | Imidazopiridazinas sustituidas con amino | |
| CL2019000986A1 (es) | 1,3 di sustituto ciclobutano o derivados de azetidina como inhibidores de prostaglandina d sintasa hematopoyética(h-pgds). | |
| BR112021017620A2 (pt) | Compostos macrocíclicos | |
| PE20220017A1 (es) | Inhibidores del kcnt1 y metodos de uso | |
| ECSP20008441A (es) | Dihidrooxadiazinonas | |
| MX2024004892A (es) | Compuestos de pirimidinodiona biciclica sustituidos con tetrahidropirano (thp). | |
| PE20160200A1 (es) | Inhibidores de bromodominios | |
| PE20121032A1 (es) | Compuesto {5-[4-(1,1-dioxo-1-tiomorfolin-4-ilmetil)-fenil]-[1,2,4] triazolo[1,5-a]piridin-2-il}-amida del acido ciclopropanocarboxilico como inhibidor de jak | |
| CO2022000481A2 (es) | Inhibidores de enzimas | |
| UY37971A (es) | Derivados de indol macrocíclicos sustituidos | |
| DOP2025000213A (es) | [1,3]tiazolo[4,5-d]-pirimidin-7-onas como inhibidores de la nox4 | |
| BR112022012130A2 (pt) | Compostos antelmínticos compreendendo uma estrutura azaindólica | |
| UY37972A (es) | Derivados de indol macrocíclicos sustituidos con cloro | |
| ECSP20080995A (es) | Derivados de tetrahidrotienopiridina nsustituidos y sus usos | |
| CL2023000061A1 (es) | Macrociclos y su uso | |
| CR20180615A (es) | Nuevos derivados de [1,2,3]triazol[4,5-d]pirimidina | |
| MX2024009805A (es) | (+)-tetrabenazina cristalina. |